Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Purchased by HealthInvest Partners AB

HealthInvest Partners AB raised its holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 17.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,940 shares of the company’s stock after acquiring an additional 4,550 shares during the quarter. HealthInvest Partners AB owned 0.07% of Soleno Therapeutics worth $1,391,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. Avanza Fonder AB purchased a new position in shares of Soleno Therapeutics in the 4th quarter valued at about $76,000. Avior Wealth Management LLC purchased a new position in Soleno Therapeutics in the fourth quarter valued at about $89,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Soleno Therapeutics during the 3rd quarter valued at approximately $155,000. Curi RMB Capital LLC acquired a new stake in shares of Soleno Therapeutics during the 3rd quarter valued at approximately $202,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Soleno Therapeutics during the 3rd quarter worth approximately $262,000. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on SLNO. Oppenheimer raised their price objective on Soleno Therapeutics from $65.00 to $73.00 and gave the company an “outperform” rating in a research note on Monday, October 28th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Lifesci Capital upgraded shares of Soleno Therapeutics to a “strong-buy” rating in a report on Tuesday, February 4th. Robert W. Baird reissued an “outperform” rating and set a $72.00 price target on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Finally, Stifel Nicolaus restated a “buy” rating and issued a $74.00 target price on shares of Soleno Therapeutics in a report on Monday, December 2nd. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $71.20.

Insider Buying and Selling at Soleno Therapeutics

In other Soleno Therapeutics news, insider Kristen Yen sold 2,340 shares of Soleno Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $46.18, for a total value of $108,061.20. Following the transaction, the insider now owns 76,605 shares in the company, valued at $3,537,618.90. This trade represents a 2.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bhatnagar Anish sold 10,937 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $496,649.17. Following the sale, the chief executive officer now directly owns 708,616 shares of the company’s stock, valued at $32,178,252.56. This represents a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 17,360 shares of company stock worth $790,119 in the last 90 days. 12.30% of the stock is owned by company insiders.

Soleno Therapeutics Trading Down 2.7 %

Soleno Therapeutics stock opened at $46.13 on Monday. The stock has a fifty day moving average price of $47.23 and a 200 day moving average price of $49.97. Soleno Therapeutics, Inc. has a 52 week low of $36.61 and a 52 week high of $60.92. The firm has a market capitalization of $1.99 billion, a P/E ratio of -13.89 and a beta of -1.46.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.